sur GENOWAY (EPA:ALGEN)
Half-year review of the liquidity contract for genOway as of December 31, 2025
The biotechnology company genOway has released key figures for its liquidity contract for the second half of 2025, managed by Portzamparc - Groupe BNP Paribas. As of December 31, 2025, the liquidity account held 16,002 genOway shares and €32,256.26 in cash. Compared to the balance sheet as of June 30, 2025, the number of shares decreased from 18,270 to 16,002, while cash increased from €25,115.23 to €32,256.26.
Since the contract was established on December 31, 2018, a significant decrease in the number of shares, initially at 28,232, has been observed. During the second half of 2025, 31,316 shares were purchased for €86,569.72, while 33,584 shares were sold for €93,710.75.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENOWAY